Halozyme Therapeutics Reports Executive Compensation Changes
Ticker: HALO · Form: 8-K · Filed: Dec 8, 2025 · CIK: 1159036
| Field | Detail |
|---|---|
| Company | Halozyme Therapeutics, Inc. (HALO) |
| Form Type | 8-K |
| Filed Date | Dec 8, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, officer-changes, director-appointments
Related Tickers: HALO
TL;DR
HALO updated exec comp plans on 12/4/25.
AI Summary
On December 4, 2025, Halozyme Therapeutics, Inc. reported changes in its executive and director compensation arrangements. The filing details adjustments to the compensatory arrangements for certain officers, indicating potential shifts in executive incentives and rewards.
Why It Matters
Changes in executive compensation can signal management's confidence in future performance or reflect adjustments to align incentives with strategic goals.
Risk Assessment
Risk Level: low — This filing primarily concerns executive compensation and director appointments, which typically have a low direct impact on the company's core business operations.
Key Players & Entities
- HALOZYME THERAPEUTICS, INC. (company) — Registrant
- December 4, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 12390 El Camino Real (address) — Principal business address
- San Diego (city) — Principal business address city
- California (state) — Principal business address state
- 92130 (zip_code) — Principal business address zip
FAQ
What specific changes were made to the compensatory arrangements for certain officers?
The filing indicates adjustments to compensatory arrangements for certain officers, but the specific details of these changes are not provided in the excerpt.
Were there any departures of directors or certain officers reported?
The filing lists 'Departure of Directors or Certain Officers' as an item of information, but the excerpt does not specify if any such departures occurred.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is dated December 4, 2025.
What is Halozyme Therapeutics, Inc.'s primary business classification according to the SIC code?
Halozyme Therapeutics, Inc. is classified under SIC code 2836, which pertains to Biological Products (No Diagnostic Substances).
In which state was Halozyme Therapeutics, Inc. incorporated?
Halozyme Therapeutics, Inc. was incorporated in Delaware.
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-12-08 17:20:13
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value HALO The Nasdaq Stock Market
Filing Documents
- halo-20251204.htm (8-K) — 30KB
- halo-20251204_g1.jpg (GRAPHIC) — 15KB
- 0001159036-25-000068.txt ( ) — 170KB
- halo-20251204.xsd (EX-101.SCH) — 2KB
- halo-20251204_lab.xml (EX-101.LAB) — 21KB
- halo-20251204_pre.xml (EX-101.PRE) — 12KB
- halo-20251204_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Halozyme Therapeutics, Inc. (Registrant) Dated: December 8, 2025 By: /s/ Mark Snyder Mark Snyder Senior Vice President, General Counsel and Corporate Secretary